BYCEMMA (U.S. Trademark Serial Number 88783462) is a United States trademark of Amgen Inc.. The goods and services include: pharmaceutical preparations for the treatment of cancer, cardiovascular diseases and disorders, inflammatory diseases and disorders, autoimmune diseases and disorders, oncological diseases and disorders, hematological diseases and disorders, tumorous diseases, inflammation, inflammatory diseases and disorders, neurological diseases and disorders and metabolic diseases and disorders . The correspondent is Timothy J. Gaul of AMGEN INC..

This trademark was filed on February 03, 2020 as United States Trademark Application Serial Number 88783462. This trademark application is still pending and does not yet have a registration number.

Trademark PTO Status History

July 04, 2022 – ABANDONMENT – NO USE STATEMENT FILED

September 18, 2021 – NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED

September 16, 2021 – SOU EXTENSION 2 GRANTED

September 16, 2021 – SOU EXTENSION 2 FILED

September 16, 2021 – TEAS EXTENSION RECEIVED

May 06, 2021 – NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED

May 04, 2021 – SOU EXTENSION 1 GRANTED

May 04, 2021 – SOU EXTENSION 1 FILED

View full trademark status information at USPTO

Ownership History

Amgen Inc.

Amgen Inc.

View documents on file at USPTO

File a Trademark or Get Help With Trademark Law

Select IP monitors top trademarks which have been allowed and granted worldwide. We are experts in trademark law. If you are interested in connecting with an IP law attorney or patent law attorney, please contact us via the contact form.